Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial.

Toru KinouchiJiro Terada Seiichiro SakaoKen KoshikawaTsuyoshi Sasaki Atsuhiko SugiyamaShun SatoNoriko SakumaMitsuhiro AbeKohei ShikanoNami HayamaYuki ShikoYoshihito OzawaShinobu IkedaTakuji SuzukiKoichiro Tatsumi

Published in: Respirology (Carlton, Vic.) (2022)

Overall, ATO-OXY therapy does not reduce AHI in Japanese OSA patients, although AHI was decreased in a proportion of patients. Future studies for identifying treatment response group characteristics are warranted.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
clinical trial
stem cells
obstructive sleep apnea
randomized controlled trial
study protocol
depressive symptoms
attention deficit hyperactivity disorder
mesenchymal stem cells
phase ii
current status